Literature DB >> 17301689

CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure.

Johanna Sistonen1, Antti Sajantila, Oscar Lao, Jukka Corander, Guido Barbujani, Silvia Fuselli.   

Abstract

BACKGROUND AND
OBJECTIVE: CYP2D6, a member of the cytochrome P450 superfamily, is responsible for the metabolism of about 25% of the commonly prescribed drugs. Its activity ranges from complete deficiency to excessive activity, potentially causing toxicity of medication or therapeutic failure with recommended drug dosages. This study aimed to describe the CYP2D6 diversity at the global level.
METHODS: A total of 1060 individuals belonging to 52 worldwide-distributed populations were genotyped at 12 highly informative variable sites, as well as for gene deletion and duplications. Phenotypes were predicted on the basis of haplotype combinations. RESULTS AND
CONCLUSIONS: Our study shows that (i) CYP2D6 diversity is far greater within than between populations and groups thereof, (ii) null or low-activity variants occur at high frequencies in various areas of the world, (iii) linkage disequilibrium is lowest in Africa and highest in the Americas. Patterns of variation, within and among populations, are similar to those observed for other autosomal markers (e.g. microsatellites and protein polymorphisms), suggesting that the diversity observed at the CYP2D6 locus reflects the same factors affecting variation at random genome markers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301689     DOI: 10.1097/01.fpc.0000239974.69464.f2

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  112 in total

1.  Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations.

Authors:  Andrea Gaedigk; Maria Isidoro-García; Robin E Pearce; Santiago Sánchez; Virginia García-Solaesa; Carolina Lorenzo-Romo; Gloria Gonzalez-Tejera; Susan Corey
Journal:  Eur J Clin Pharmacol       Date:  2010-05-16       Impact factor: 2.953

2.  Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.

Authors:  Victoria M Pratt; Barbara Zehnbauer; Jean Amos Wilson; Ruth Baak; Nikolina Babic; Maria Bettinotti; Arlene Buller; Ken Butz; Matthew Campbell; Chris Civalier; Abdalla El-Badry; Daniel H Farkas; Elaine Lyon; Saptarshi Mandal; Jason McKinney; Kasinathan Muralidharan; LeAnne Noll; Tara Sander; Junaid Shabbeer; Chingying Smith; Milhan Telatar; Lorraine Toji; Anand Vairavan; Carlos Vance; Karen E Weck; Alan H B Wu; Kiang-Teck J Yeo; Markus Zeller; Lisa Kalman
Journal:  J Mol Diagn       Date:  2010-10-01       Impact factor: 5.568

3.  Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case report.

Authors:  Maximilian Gahr; Regina Gastl; Markus A Kölle; Carlos Schönfeldt-Lecuona; Roland W Freudenmann
Journal:  J Med Case Rep       Date:  2012-02-06

4.  CYP2D6*4 allele and breast cancer risk: is there any association?

Authors:  Ana Fernández-Santander; Miguel del Saz Sánchez; Armando Tejerina Gómez; Fernando Bandrés Moya
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

5.  Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.

Authors:  T M Dodgen; C De J Labuschagne; A van Schalkwyk; F E Steffens; A Gaedigk; A D Cromarty; M Alessandrini; M S Pepper
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

Review 6.  CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.

Authors:  Jonas A de Souza; Olufunmilayo I Olopade
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

7.  Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Authors:  Matthew P Goetz; James X Sun; Vera J Suman; Grace O Silva; Charles M Perou; Yusuke Nakamura; Nancy J Cox; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; David Chen; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; Krishna R Kalari; Henry L Gomez; Ana M Gonzalez-Angulo; Octavio Burgues; Hiltrud B Brauch; James N Ingle; Mark J Ratain; Roman Yelensky
Journal:  J Natl Cancer Inst       Date:  2014-12-08       Impact factor: 13.506

8.  Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.

Authors:  Eva Maria Staehli Hodel; Chantal Csajka; Frédéric Ariey; Monia Guidi; Abdunoor Mulokozi Kabanywanyi; Socheat Duong; Laurent Arthur Decosterd; Piero Olliaro; Hans-Peter Beck; Blaise Genton
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

9.  CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.

Authors:  Andrea Gaedigk; Uwe Fuhr; Charlene Johnson; L Anick Bérard; Dianne Bradford; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-01       Impact factor: 2.533

Review 10.  Pharmacogenetics and pharmacogenomics of anticancer agents.

Authors:  R Stephanie Huang; Mark J Ratain
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.